<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03794180</url>
  </required_header>
  <id_info>
    <org_study_id>TJ003234RAR101</org_study_id>
    <nct_id>NCT03794180</nct_id>
  </id_info>
  <brief_title>Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects</brief_title>
  <official_title>First-in-Human, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of TJ003234 (Anti-Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) Monoclonal Antibody) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Mab Biopharma Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Mab Biopharma Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TJ003234RAR101 is a first-in-human (FIH), single-center, randomized, double-blind,
      placebo-controlled, single ascending dose study of TJ003234 in healthy adults to determine
      whether TJ003234 is safe and tolerated when administered as an intravenous (IV) infusion and
      to determine the maximum dose tolerated (MTD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Actual">September 5, 2019</completion_date>
  <primary_completion_date type="Actual">September 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Profile: AEs</measure>
    <time_frame>Up to 85 days after study drug administration</time_frame>
    <description>Incidence of Adverse Events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Up to 85 days after study drug administration</time_frame>
    <description>Determine Maximum Tolerated Dose of TJ003234</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameters: Tmax</measure>
    <time_frame>Up to 85 days after study drug administration</time_frame>
    <description>Time of peak concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameters: Cmax</measure>
    <time_frame>Up to 85 days after study drug administration</time_frame>
    <description>Maximal Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameters: T1/2</measure>
    <time_frame>Up to 85 days after study drug administration</time_frame>
    <description>Investigational product (IP) half-life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameters: CL</measure>
    <time_frame>Up to 85 days after study drug administration</time_frame>
    <description>Investigational Product (IP) Clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameters: AUC∞</measure>
    <time_frame>Up to 85 days after study drug administration</time_frame>
    <description>Area under the curve from time zero extrapolated to infinity (AUC∞)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies (ADA)</measure>
    <time_frame>Up to 85 days after study drug administration</time_frame>
    <description>Incidence and concentration of anti-drug antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Adult Subjects</condition>
  <arm_group>
    <arm_group_label>TJ003234</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg via single IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 mg/kg via single IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ003234</intervention_name>
    <description>Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline</description>
    <arm_group_label>TJ003234</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to understand and willing to sign the informed consent form (ICF)

          -  Healthy subjects 18-70 years of age

          -  If of childbearing potential, agree to use protocol-specified contraception

          -  Body mass index (BMI) 19.0-32.0 kg/m^2

          -  Blood pressure ≤ 139/89 mm Hg

          -  Subjects are able to follow the study protocol and complete the trial

        Exclusion Criteria:

          -  Current use of tobacco or nicotine-containing products or illicit drug use

          -  History of severe allergic or anaphylactic reaction to a therapeutic drug or severe
             seasonal allergies

          -  Any known pulmonary disease

          -  Use of any prescription, investigational drugs, herbal supplements, or nonprescription
             drugs within 1 month or 5 half-lives (whichever is longer) prior to study drug
             administration, or dietary supplements within 1 week prior to study drug
             administration, unless, in the opinion of the Investigator and Sponsor, the medication
             will not interfere with the study

          -  Abnormal hematological and chemistry laboratory values &gt;10% above upper limit of
             normal (ULN) or &gt;10% below the lower limit of normal (LLN). Absolute neutrophil count
             (ANC) ≤ 1000 cells/mm^3

          -  Use of any biologic drugs in the last 120 days prior to dosing.

          -  Immunization with a live or attenuated vaccine within 4 weeks prior to study drug
             administration

          -  Prior treatment with any biologic anti-GM-CSF or GM-CSF receptor antagonists

          -  ADA screening positive

          -  Subjects who have a history of documented autoimmune disease, even if not clinically
             severe or never treated with systemic steroids or immunosuppressive agents

          -  A positive alcohol test and/or urine drug screen for substance of abuse at screening
             or upon check-in to the clinical site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Xu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>I-Mab Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaron</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 28, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-GM-CSF agents</keyword>
  <keyword>GM-CSF/GM-CSFR (GM-CSF receptor) antibody</keyword>
  <keyword>colony-stimulating factor 2</keyword>
  <keyword>monoclonal antibody</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

